Literature DB >> 18271004

Characteristics of testicular dysgenesis syndrome and decreased expression of SRY and SOX9 in Frasier syndrome.

Valérie Schumacher1, Banu Gueler, Leendert H J Looijenga, Jan Ulrich Becker, Kerstin Amann, Rainer Engers, Joerg Dotsch, Hans Stoop, Wolfgang Schulz, Brigitte Royer-Pokora.   

Abstract

Frasier syndrome (FS) is characterized by chronic renal failure in early adulthood, varying degrees of gonadal dysgenesis, and a high risk for gonadal germ cell malignancies, particularly gonadoblastoma. Although it is known to arise from heterozygous splice mutations in intron 9 of the Wilms' tumor gene 1 (WT1), the mechanisms by which these mutations result in gonadal dysgenesis in humans remain obscure. Here we show that a decrease in WT1 + KTS isoforms due to disruption of alternative splicing of the WT1 gene in a FS patient is associated with diminished expression of the transcription factors SRY and SOX9 in Sertoli cells. These findings provide the first confirmation in humans of the results obtained by others in mice. Consequently, Sertoli cells fail to form the specialized environment within the seminiferous tubules that normally houses developing germ cells. Thus, germ cells are unable to fully mature and are blocked at the spermatogonial-spermatocyte stage. Concomitantly, subpopulations of the malignant counterpart of primordial germ cells/gonocytes, the intratubular germ cell neoplasia unclassified type (ITGCN), are identified. Furthermore, dysregulated Leydig cells produce insufficient levels of testosterone, resulting in hypospadias. Collectively, the impaired spermatogenesis, hypospadias and ITGCN comprise part of the developmental disorder known as 'testicular dysgenesis syndrome' (TDS), which arises during early fetal life. The data presented here show that critical levels of WT1 + KTS, SRY and SOX9 are required for normal Sertoli cell maturation, and subsequent normal spermatogenesis. To further study the function of human Sertoli cells in the future, we have established a human cell line.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18271004     DOI: 10.1002/mrd.20889

Source DB:  PubMed          Journal:  Mol Reprod Dev        ISSN: 1040-452X            Impact factor:   2.609


  13 in total

1.  Altered microRNA expression in patients with non-obstructive azoospermia.

Authors:  Jie Lian; Xiansheng Zhang; Hui Tian; Ning Liang; Yong Wang; Chaozhao Liang; Xin Li; Fei Sun
Journal:  Reprod Biol Endocrinol       Date:  2009-02-11       Impact factor: 5.211

2.  Current insights into the sulfatase pathway in human testis and cultured Sertoli cells.

Authors:  K Hartmann; J Bennien; B Wapelhorst; K Bakhaus; V Schumacher; S Kliesch; W Weidner; M Bergmann; J Geyer; D Fietz
Journal:  Histochem Cell Biol       Date:  2016-09-29       Impact factor: 4.304

3.  Copy number variation in patients with disorders of sex development due to 46,XY gonadal dysgenesis.

Authors:  Stefan White; Thomas Ohnesorg; Amanda Notini; Kelly Roeszler; Jacqueline Hewitt; Hinda Daggag; Craig Smith; Erin Turbitt; Sonja Gustin; Jocelyn van den Bergen; Denise Miles; Patrick Western; Valerie Arboleda; Valerie Schumacher; Lavinia Gordon; Katrina Bell; Henrik Bengtsson; Terry Speed; John Hutson; Garry Warne; Vincent Harley; Peter Koopman; Eric Vilain; Andrew Sinclair
Journal:  PLoS One       Date:  2011-03-07       Impact factor: 3.240

4.  A 46,XY female DSD patient with bilateral gonadoblastoma, a novel SRY missense mutation combined with a WT1 KTS splice-site mutation.

Authors:  Remko Hersmus; Yvonne G van der Zwan; Hans Stoop; Pascal Bernard; Rajini Sreenivasan; J Wolter Oosterhuis; Hennie T Brüggenwirth; Suzan de Boer; Stefan White; Katja P Wolffenbuttel; Marielle Alders; Kenneth McElreavy; Stenvert L S Drop; Vincent R Harley; Leendert H J Looijenga
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

Review 5.  Insights into female germ cell biology: from in vivo development to in vitro derivations.

Authors:  Dajung Jung; Kehkooi Kee
Journal:  Asian J Androl       Date:  2015 May-Jun       Impact factor: 3.285

6.  Reference gene validation for RT-qPCR, a note on different available software packages.

Authors:  Ward De Spiegelaere; Jutta Dern-Wieloch; Roswitha Weigel; Valérie Schumacher; Hubert Schorle; Daniel Nettersheim; Martin Bergmann; Ralph Brehm; Sabine Kliesch; Linos Vandekerckhove; Cornelia Fink
Journal:  PLoS One       Date:  2015-03-31       Impact factor: 3.240

7.  Membrane transporters for sulfated steroids in the human testis--cellular localization, expression pattern and functional analysis.

Authors:  Daniela Fietz; Katharina Bakhaus; Britta Wapelhorst; Gary Grosser; Sabine Günther; Jörg Alber; Barbara Döring; Sabine Kliesch; Wolfgang Weidner; Christina E Galuska; Michaela F Hartmann; Stefan A Wudy; Martin Bergmann; Joachim Geyer
Journal:  PLoS One       Date:  2013-05-08       Impact factor: 3.240

8.  The cancer/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas.

Authors:  Daniel Nettersheim; Isabell Arndt; Rakesh Sharma; Stefanie Riesenberg; Sina Jostes; Simon Schneider; Michael Hölzel; Glen Kristiansen; Hubert Schorle
Journal:  Br J Cancer       Date:  2016-07-21       Impact factor: 7.640

9.  A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatment.

Authors:  Daniel Nettersheim; Sina Jostes; Martin Fabry; Friedemann Honecker; Valerie Schumacher; Jutta Kirfel; Glen Kristiansen; Hubert Schorle
Journal:  Oncotarget       Date:  2016-11-15

10.  On the origin of germ cell neoplasia in situ: Dedifferentiation of human adult Sertoli cells in cross talk with seminoma cells in vitro.

Authors:  Cornelia Fink; Nelli Baal; Jochen Wilhelm; Poonam Sarode; Roswitha Weigel; Valérie Schumacher; Daniel Nettersheim; Hubert Schorle; Carmen Schröck; Martin Bergmann; Sabine Kliesch; Monika Kressin; Rajkumar Savai
Journal:  Neoplasia       Date:  2021-06-18       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.